This grant will support the development of Brain-Spine Interface (BSI) technology aimed at restoring upper extremity mobility and function in people with spinal cord injuries.
EINDHOVEN, Netherlands and LAUSANNE, Switzerland, June 16, 2022-(BUSINESS WIRE)-ONWARD Medical NV (Euronext: ONWD), a medical technology company that creates innovative therapies to restore movement, freedom and health to people with spinal cord injuries, has received a grant from the European Innovation Council (IEC) to support the development of its innovative Brain-Spine Interface technology to restore upper limb movement and function.
This press release contains multimedia elements. See the full press release here: https://www.businesswire.com/news/home/20220616005580/fr/
ONWARD ARC Brain Spine Interface (Graphic: Business Wire)
The EUR 3.6 million grant was awarded to ONWARD and its research partners: EPFL, one of the world’s leading neuroscience research organizations; CEA-Clinatec, the Edmond J. Safra Biomedical Research Center, founded by Professor Alim-Louis Benabid, specialist in medical equipment for the diagnosis and treatment of neurodegenerative diseases and motor diseases; and Sint Maartenskliniek, a leading rehabilitation center for people with spinal cord injuries in the Netherlands. The project is called “Brain-Spine Interfaces to Reverse Upper- and Lower-limb Paralysis”. Under the terms of the grant, ONWARD will receive EUR 1.2 million.
The consortium will use the grant to fund integration between ARC therapiesIM from ONWARD, which applies targeted and programmed spinal cord stimulation, and Clinatec’s WIMAGINE solution, a fully implantable device approved for acute use in clinical trials in two European countries , which records and decodes brain cortical signals to predict human movement. intentions. The consortium will also conduct two clinical feasibility studies using its BSI system, evaluating its use for upper and lower limb control and rehabilitation, with two participants in each study. Finally, the clinicians of Sint-Maartenskliniek will express their opinion on the usability of the system. What will be delivered is a set of specifications for a commercially viable BSI system for people with spinal cord injuries.
“This IRC grant confirms ONWARD’s position as a leader in the emerging and growing sector of brain-spinal cord interface technologies,” said Dave Marver, CEO of ONWARD. “In conjunction with the intellectual property rights option acquired from EPFL in March, we now have key elements to develop and pave the way for BSI technology to assist people with spinal cord injuries. “
To learn more about ARC therapy and ONWARD’s approach to restoring movement, freedom and health to people with spinal cord injuries, please visit ONWD.com.
ONWARD is a medical technology company that makes innovative therapies to restore movement, freedom and health to people with spinal cord injuries. ONWARD’s work is based on more than a decade of basic and preclinical scientific research conducted in the world’s leading neuroscience laboratories. ONWARD ARC therapy, which can be delivered through implantable systems (ARCIM) or external (ARCEX), is designed to provide targeted, programmed spinal cord stimulation to restore movement and other functions to people with spinal cord injuries, thereby improving their quality of life. ONWARD has received three breakthrough device designations from the FDA, covering the same ARCIM and the CRAEX. Up-LIFT, the company’s first pivotal trial conducted for the FDA, completed enrollment in December 2021 with a total of 65 subjects worldwide. The company recently completed the first-in-human use of its ARC neurostimulatorIM in May 2022.
ONWARD’s headquarters are located on the High Tech Campus in Eindhoven, Netherlands. The company has a large team in Lausanne, Switzerland, and is expanding its US presence in Boston, Massachusetts. For more information about the company, visit ONWD.com. To view our 2022 financial calendar, please visit IR.ONWD.com.
Certain statements, ideas and opinions in this press release are in nature forward -looking, and reflect the expectations and plans of the Company or its directors in relation to future events. By their nature, future statements involve risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied by the statements expected. These risks, uncertainties and assumptions may affect the financial results and performance of the plans and events described herein. Many factors, including changes in demand, competition and technology, can cause actual events, performance or results to differ materially from expected developments. Forward-looking statements contained in this press release relating to past trends or activity should not be considered as an indication that such trends or activity will continue in the future. Accordingly, the Company undertakes no obligation to issue any updates or changes to the forward-looking statements contained in this statement if there are any changes to expectations or to events, conditions, assumptions or circumstances on which these expected statements are based. . The Company, its advisors or representatives, its subsidiaries or their officers or employees do not guarantee that the assumptions on which future statements are based are without error, and disclaims all responsibility for accuracy. future statements in future content. here. , and about achieving expected progress. Readers are warned not to place too much reliance on hopeful statements, which speak only to its date.
The text of the press release resulting from a translation should not be considered official. The only true version of the press release is the press release in its original language. The translation always has to be compared to the source text, which will set a precedent.
Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20220616005580/en/
Andy Dolan |